| HOME >> MEDICINE >> TECHNOLOGY |
(13,627)(4,367)Non-GAAP operating expenses$83,741$66,241Non-GAAP operating incomeGAAP operating income$15,747$25,323Restructuring and transformation costs
25,0844,329Non-GAAP operating income$40,831$29,652Non-GAAP income before taxesGAAP income before taxes$13,205$25,463Restructuring and transformation costs
25,0844,329Non-GAAP income before taxes$38,289$29,792Non-GAAP net incomeGAAP net income$9,904$18,252Restructuring and transformation costs
25,0844,329Tax benefit associated with non-GAAP items
(8,569)(595)Non-GAAP net income$26,419$21,986Non-GAAP net income per common share assuming dilutionGAAP net income per common share assuming dilution$0.19$0.36Non-GAAP items after tax per common share assuming dilution
$
0.31$
0.07Non-GAAP net income per common share assuming dilution$0.50$0.43Presented below are additional Constant Currency performance measures. We measure different components of our business at constant currency. We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates. These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of 0.833 Euro to 1.00 US Dollar and 110 Yen to 1.00 US Dollar. They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K
Three Months Ended12/29/201212/31/2011Non-GAAP revenuesGAAP revenue$247,395$191,160Foreign currency effects(16,600)(15,498)Non-GAAP revenue - constant currency$230,795$175,662Non-GAAP net incomeNon-GAAP net income, adjusted for restructuring and transformation costs$26,419$21,986Foreign currency effects
(8,068)(6,878)Income tax associated with foreign currency effects
2,5011,803Non-GAAP net inco
'/>"/>
| SOURCE Haemonetics Corporation Copyright©2012 PR Newswire. All rights reserved |